Add-on therapies to metformin for type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Add-on therapies to metformin for type 2 diabetes.

Add-on therapies to metformin for type 2 diabetes.

http://www.wikidata.org/entity/Q37818234

about

Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine.Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs.Metformin + saxagliptin for type 2 diabetes.Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization.Urinary Smad1 is a new biomarker for diagnosis and evaluating the severity of diabetic nephropathy.

P2860

Q35214420-E21B6016-D849-4FF6-99E8-CCAF51C97C7F Q36077002-E9F31EA6-0EAE-46D9-AC55-042CB8F2B5ED Q37207121-E2428111-FE2F-46AB-A661-A1DB901D2E43 Q37225390-446A6B75-74B7-40D6-8512-82BE1658485A Q37965618-F7385D4A-2587-4B67-8979-D03BE9853BB9 Q37991385-55CE5825-2B6A-4279-A9A4-FD5894CBA7A0 Q39294616-1D9BA663-D872-41AE-8E8F-E068DF487885 Q47783568-86FE8993-00BA-4E4E-9906-BDC5A85B9B7B

P2860

Add-on therapies to metformin for type 2 diabetes.

http://www.wikidata.org/entity/Q37818234

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 December 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Add-on therapies to metformin for type 2 diabetes.

@en

Add-on therapies to metformin for type 2 diabetes.

@nl

type

label

Add-on therapies to metformin for type 2 diabetes.

@en

Add-on therapies to metformin for type 2 diabetes.

@nl

prefLabel

Add-on therapies to metformin for type 2 diabetes.

@en

Add-on therapies to metformin for type 2 diabetes.

@nl

P1433

Q37818234-6BAD5EF5-2E37-4B70-B78D-B75C842DFE88

P1476

Q37818234-E45CB794-E870-4877-99A8-ADE8CDB8635E

P2093

Q37818234-86AFD4F7-A6A5-479A-BDF8-7F1CE40B57D4

P2860

Q37818234-002969BC-324C-4C81-979D-9C3DAC96AFF3

Q37818234-035BB903-0D31-44D1-BAD4-516B5C18989F

Q37818234-051512F6-33B7-4186-98EF-FA94646CAD03

Q37818234-05989A72-7AEF-4794-9597-BAECA52C2FC9

Q37818234-06A7380A-0E7E-46D3-A2E7-CA710CC163F2

Q37818234-09B88EAB-F0DE-4E55-9463-CD54C06C2534

Q37818234-0C487ADD-9E3E-46C2-AE12-1E2584814748

Q37818234-1134B88D-4EEC-47EC-927E-1128D79E7FEB

Q37818234-13891A2F-179C-4F98-8B9A-8C45E847005C

Q37818234-1624C1A7-EC47-4B8C-B92C-90983EEEAD34

P304

Q37818234-6E488DAD-068B-4155-AA4B-B0573B96BB80

P31

Q37818234-CE1323D6-87D7-4548-BB93-52FCCE6BB57A

Q37818234-f852c223-2f1d-485d-843b-e5961ebf4861

P356

Q37818234-8D088AF9-A193-4345-82FF-8D8A98C039A1

P407

Q37818234-BC0A5AA4-6ACB-4DD1-8B23-BF8CD8965472

P433

Q37818234-83460EC7-B439-4600-A350-D6FB9E4F72BA

P478

Q37818234-1AE6546E-E10D-4E51-A369-475FE8742101

P577

Q37818234-4D8BA4A2-0071-4662-979B-4EAA04D8F579

P698

Q37818234-5AB72E99-507D-4221-AF88-5E5FB45D7111

P921

Q37818234-342BF489-EDB4-43E5-9D8D-388F56728CCC

Q37818234-E0F610B8-F800-4216-BA50-8FCE31D06BD3

P356

14656566.2011.542150

P1433

Expert Opinion on Pharmacotherapy

P1476

Add-on therapies to metformin for type 2 diabetes.

@en

P2093

Mansur Shomali

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

P304

47-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2011.542150

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21142694

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes